Company / Net Income
INOVIO PHARMACEUTICALS, INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$107.3M
FY2025
5-year range
-$303.7M / -$107.3M
FY2021-FY2025
Trend
+20.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$304M to -$107M over the past 2 years.
Based on SEC 10-K filings.
-$107M in FY2025.
Improved from -$304M to -$107M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 20.6% year-over-year.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$107.3M | +20.6% |
| FY2024 | -$135.1M | +55.5% |
| FY2023 | -$303.7M | -82.5% |
| FY2022 | -$166.4M | -39.4% |
| FY2021 | -$119.4M | -23.1% |
| FY2020 | -$97.0M | -9.9% |
| FY2019 | -$88.2M | -19.6% |
| FY2018 | -$73.7M | -152.6% |
| FY2017 | -$29.2M | +19.2% |
| FY2016 | -$36.1M | +45.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026